{
    "2021-03-17": [
        [
            {
                "time": "2021-03-15",
                "original_text": "Did Pfizer Just Trip Up AbbVie's Chances For A New Arthritis Drug?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "AbbVie",
                        "arthritis drug"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-03-16",
                "original_text": "FDA Pushback on AbbVie Drug Raises More Alarms for Biotechnology",
                "features": {
                    "keywords": [
                        "FDA",
                        "AbbVie",
                        "biotechnology"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "REFILE-UPDATE 1-U.S. FDA extends review period for expanded use of Abbvie's arthritis drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "review period",
                        "arthritis drug"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-18",
                "original_text": "U.S. FDA extends review period for expanded use of Abbvie's arthritis drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "review period",
                        "arthritis drug"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-19",
                "original_text": "AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "psoriatic arthritis"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-20",
                "original_text": "The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M&A. What It Means for the Industry.",
                "features": {
                    "keywords": [
                        "FTC",
                        "M&A",
                        "pharmaceutical"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-03-21",
                "original_text": "AbbVie Slumps After FDA Extends Psoriatic Arthritis Drug Review",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "drug review"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-22",
                "original_text": "4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package",
                "features": {
                    "keywords": [
                        "pharma stocks",
                        "stimulus package"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}